Biogen GAZYVA — After Second GAZYVA Threshold Date remained flat by 0.0% to 35.0% in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 35.0% to 35.0%. Over 2 years (FY 2023 to FY 2025), GAZYVA — After Second GAZYVA Threshold Date shows relatively stable performance with a 0.0% CAGR.
Entering this period typically signals that the product has achieved significant market maturity or scale, triggering revised financial arrangements.
This indicator marks the operational period following the achievement of a secondary performance milestone related to pr...
Similar to post-milestone phases in pharmaceutical licensing or co-development agreements.
biib_segment_gazyva_after_second_gazyva_threshold_date| Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% | 35% |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | +0.0% | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |